Linda Llewelyn, the Chief People Officer of Health Catalyst Inc. (NASDAQ: ), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On January 15, Llewelyn sold 6,442 shares of common stock at an average price of $5.7976 per share, amounting to approximately $37,348. Following this transaction, Llewelyn retains ownership of 92,260 shares in the company. This sale was made under a pre-arranged trading plan established in March 2024, pursuant to Rule 10b5-1. The sale comes as Health Catalyst is trading near its 52-week low of $5.35, with the stock down 20% previously. week. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts projecting a profit this year despite recent market pressure. InvestingPro subscribers have access to 8 additional key insights about Health Catalyst, including detailed financial health scores and comprehensive valuation metrics.

In other recent news, Health Catalyst is the focus of several important developments. The company announced a definitive agreement to acquire Upfront Healthcare Services (NASDAQ :)), a provider of a patient engagement platform, expected to close in the first quarter of 2025. This acquisition aims to improve the current Health Catalyst’s patient engagement portfolio and streamlining patient care.

Health Catalyst also disclosed positive financial results in the third quarter for 2024, with a mix of revenue shifting back to software. Analyst firms such as KeyBanc Capital Markets, Piper Sandler, and Stephens showed optimism for the company’s performance, upgrading the stock and raising the price target. KeyBanc upgraded Health Catalyst from Sector Weight to Overweight, while Piper Sandler and Stephens raised their price target on the company’s stock.

In terms of analyst ratings, RBC Capital cut the stock target for Health Catalyst to $7, maintaining a Sector Perform rating. This decision reflects the company’s cautious stance as they monitor Health Catalyst’s ability to convert new client reservations into continued revenue growth. However, the company expressed optimism about Health Catalyst’s booking outlook for 2025, expecting around 40 new clients.

These are recent developments that provide investors with insights into Health Catalyst’s financial health and growth trajectory. The company’s actions and financial results, combined with the views of various analyst firms, offer a snapshot of Health Catalyst’s current business landscape.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.